Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ: ANTX )

1.410 +0.060 (+4.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AN2 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
US Stocks Mixed; Trimble Issues Weak Outlook
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.05% to 38,651.80 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected in summer 2024. 
Via Benzinga
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. (NASDAQ: MNDY) fell sharply in today’s pre-market trading after... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
$16M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Jefferies Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Participate in Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
From AN2 Therapeutics, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Dip
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Lennar To Rally Around 14%? Plus Keybanc Predicts $5,120 For This Stock
  Keybanc boosted the price target on Lennar Corporation (NYSE: LEN) from $89 to $100. Lennar shares fell 0.4% to close at $88.03 on Friday. 
Via Benzinga
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From AN2 Therapeutics, Inc.
Via GlobeNewswire
AN2 Therapeutics to Present at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via GlobeNewswire
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
From AN2 Therapeutics, Inc.
Via GlobeNewswire
Uber, Lyft, AZZ And Other Big Losers From Tuesday
U.S. stocks closed mixed with the Nasdaq Composite dropping more than 100 points on Tuesday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS